COMPARING THE EFFECTIVENESS OF ORAL ISOTRETINOIN AND CYPROTERONE COMPOUND IN ACNE TREATMENT AMONG ADULT FEMALES WITH CUTANEOUS HYPERANDROGENISM: A PROSPECTIVE STUDY.

Smita Rani  Samal; Sujeet Kumar  Singh; Itismita  Sahu; Swadesh Kumar  Mohanty

doi:10.51168/sjhrafrica.v5i6.1290

Authors

Smita Rani Samal Assistant Professor, Department of Dermatology, SCB Medical College and Hospital, Cuttack, India.
Sujeet Kumar Singh Senior Resident, Department of Dermatology, SCB Medical College and Hospital, Cuttack, India.
Itismita Sahu Senior Resident, Department of Dermatology, SCB Medical College and Hospital, Cuttack, India.
Swadesh Kumar Mohanty Senior Resident, Department of Pulmonary Medicine, Sleep and Critical Care, All India Institute of Medical Sciences, Bhubaneswar, India

DOI:

https://doi.org/10.51168/sjhrafrica.v5i6.1290

Keywords:

Acne, cyproterone compound, hyperandrogenism, isotretinoin

Abstract

Background:

Acne is a complex illness caused by androgenic stimulation of the sebaceous glands. As a result, combined oral contraceptives (COCs) including anti-androgenic progestogens are good candidates for acne treatment. The purpose of this study is to compare the effectiveness of oral isotretinoin and cyproterone compound in the treatment of nodulocystic acne, in adult females with signs of cutaneous hyperandrogenism.

Materials and Methods:

Thirty female patients with SAHA syndrome were randomly assigned into two groups of fifteen each. Group A got cyproterone compound (35 μg ethinyl estradiol and 2mg cyproterone acetate) starting day 5 of the menstrual cycle. Group B got isotretinoin at a dose of 0.5mg/kg daily. All recruited patients got topical benzoyl peroxide 3.5% gel regularly. SPSS was used to do statistical analysis. P-values < 0.05 were considered significant.

Results:

Despite a consistent reduction in ASI score in both groups, according to both physician (P = 0.63) and patient (P = 0.25) assessment, the cyproterone compound was not statistically more successful than traditional treatment of nodulocystic acne at the end of the trial. Patients in both groups reported minor and acceptable side effects, except in two cases.

Conclusion:

This study found that cyproterone compound is not more effective than isotretinoin in the treatment of nodulocystic acne in patients with SAHA syndrome or cutaneous hyperandrogenism. Indeed, additional research is needed to assess the efficacy of cyproterone molecules (independent of testosterone level) and isotretinoin in people with just nodulocystic acne.

Recommendation:

Oral isotretinoin is recommended for treating nodulocystic acne in patients with cutaneous hyperandrogenism due to its comparable efficacy to cyproterone compound and established effectiveness in reducing acne lesions. Further research should compare these treatments regardless of androgen levels in nodulocystic acne patients.